New Preclinical Data Reinforces Non-Hallucinogenic Profile of Enveric's Lead Candidate EB-003
ENVB sits 33% above its 52-week low of $1.25.
Summary
Enveric reported new preclinical data from a GloSensor cAMP assay showing its lead neuroplastogen EB-003 consistently falls within the non-hallucinogenic range. The results align with a 2026 Nature paper linking 5-HT2A Gi signaling to hallucinogenic potential, adding mechanistic validation. This builds on prior BRET assay data and supports the company's strategy to develop a non-hallucinogenic psychedelic-inspired therapy. The FDA's recent final guidance on psychedelic drug development highlights the regulatory advantages of a non-hallucinogenic profile, potentially enabling simpler trials and broader access. With a market cap of only $6.2M and a going concern warning, positive pipeline progress is critical for survival. The company is advancing EB-003 toward IND-enabling studies and a planned Phase 1 trial.
At the time of this announcement, ENVB was trading at $1.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2M. The 52-week trading range was $1.25 to $17.64. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.